Navigation Links
Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
Date:5/11/2012

ANN ARBOR, Mich., May 11, 2012  /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that to improve its corporate governance and strengthen the Board, it has split the roles of Chairman and Chief Executive Officer, and appointed Jeffrey J. Kraws to serve as its independent, non-executive Chairman of the Board. Mr. Kraws has served on the Company's Board of Directors since January 2006, and will continue to serve on the Compensation and Nominations Committees.

Mr. Kraws is Chief Executive Officer and co-founder of Crystal Research Associates. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry. Among other awards, he was given a "5-Star Rating" in 2001 by Zacks and was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding Crystal Research Associates in 2003, Mr. Kraws served as co-president of The Investor Relations Group, a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Co.). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT A
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
2. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
3. Adeona Becomes Synthetic Biologics, Inc.
4. Startling results in synthetic chemistry presented in Nature Chemistry
5. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
6. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
7. Synthetic Biology: Emerging Global Markets
8. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
9. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
10. Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation
11. Kuros Announces Allowance of European Patent for Synthetic Biomaterials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... D.C. (March 8, 2011) -- Researchers at the University ... Texas at Dallas are reporting today at the 55th ... they are using a novel 3D cell imaging method ... providing a solution to this fundamental problem in cell ...
... 8, 2011 New technology designed to revolutionize ... its initial operating capability, the FBI announced today. ... built by Lockheed Martin, delivers an incremental replacement ... (IAFIS). NGI provides automated fingerprint and latent search ...
... Pa. -- Crabs, fishing, land use and pollution sources ... Bay area, but finding all the available information, especially ... a project of the AmericaView consortium, brings together a ... who needs them for research, planning or other studies. ...
Cached Biology News:FBI Announces Initial Operating Capability for Next Generation Identification System 2ChesapeakeView: Everything you need to know about the bay 2
Ms anti-Cyclophilin D...
... to qualitatively detect EGFR ... paraffin-embedded (FFPE) tissue sections, ... cell preparations, using Chromogenic ... Fluorescent In Situ Hybridization ...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Biology Products: